The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Efficacy and safety of monotherapy with sirukumab compared with adalimumab monotherapy in biologic-naïve patients with active rheumatoid arthritis (SIRROUND-H): a randomised, double-blind, parallel-group, multinational, 52-week, phase 3 study
Abstract
Objective This randomised, double-blind, parallel-group, phase 3 study compared monotherapy with sirukumab, an anti-interleukin-6 cytokine monoclonal antibody, with adalimumab monotherapy in patients with rheumatoid arthritis (RA). Methods Biologic-naïve patients with active RA who were inadequate responders or were intolerant to, or inappropriate for, methotrexate were randomised to subcutaneous sirukumab 100 mg every 2 weeks (n=187), sirukumab 50 mg every 4 weeks (n=186) or adalimumab 40 mg every 2 weeks (n=186). Primary endpoints at week 24 were change from baseline in Disease Activity Score in 28 joints (DAS28) using erythrocyte sedimentation rate (ESR) and proportion of patients achieving an American College of Rheumatology (ACR) 50 response; these endpoints were tested in sequential order. This study is registered at EudraCT (number: 2013-001417-32) and ClinicalTrials.gov (number: NCT02019472). Results Significantly greater improvements from baseline in mean (SD) DAS28 (ESR) were observed at week 24 with sirukumab 100 mg every 2 weeks (-2.96 (1.580)) versus adalimumab 40 mg every 2 weeks (-2.19 (1.437); P Conclusion Sirukumab monotherapy showed greater improvements in DAS28 (ESR), but similar ACR50 response rates, versus adalimumab monotherapy.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“sirukumab and adalimumab were comparable in efficacy”
From Targeting Interleukin-6 Signaling in Clinic (2019) · cites this paper as Taylor et al., 2018
In the citing paper
“A study of sirukumab monotherapy (n = 373) compared with adalimumab monotherapy (n = 186) showed the occurrence of deaths in the sirukumab arms (four patients died) but not in the adalimumab arm through 68 weeks raised safety concerns, and health authorities requested additional clinical data”
From Targeting Interleukin-6 Signaling in Clinic (2019) · cites this paper as Taylor et al., 2018
Citations
Cites
2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis
Singh, J. A., Saag, K. G., Bridges, S. L., Akl, E. A., Bannuru, R. R., Sullivan, M. C., Vaysbrot, E., McNaughton, C., Osani, M., Shmerling, R. H., et al. (2016) · Arthritis & Rheumatology · doi:10.1002/art.39480 · Cited by 2,777
Smolen, J. S., Landewé, R., Bijlsma, J., Burmester, G., Chatzidionysiou, K., Dougados, M., Nam, J., Ramiro, S., Voshaar, M., van Vollenhoven, R., et al. (2017) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2016-210715 · Cited by 2,057
Breedveld, F. C., Weisman, M. H., Kavanaugh, A. F., Cohen, S. B., Pavelká, K., van Vollenhoven, R., Sharp, J. T., Perez, J. L., & Spencer-Green, G. (2005) · Arthritis & Rheumatism · doi:10.1002/art.21519 · Cited by 1,791
Smolen, J. S., Breedveld, F. C., Burmester, G. R., Bykerk, V. P., Dougados, M., Emery, P., Kvien, T. K., Navarro-Compán, M. V., Oliver, S. M., Schoels, M., et al. (2015) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2015-207524 · Cited by 1,481
Interleukin-6 and chronic inflammation.
Gabay, C. (2006) · Arthritis Research & Therapy · doi:10.1186/ar1917 · Cited by 1,447
Bartelds, G. M. (2011) · JAMA · doi:10.1001/jama.2011.406 · Cited by 809
IL-6 in autoimmune disease and chronic inflammatory proliferative disease
Ishihara, K., & Hirano, T. (2002) · Cytokine & Growth Factor Reviews · doi:10.1016/s1359-6101(02)00027-8 · Cited by 807
Therapeutic strategies for the clinical blockade of IL-6/gp130 signaling
Jones, S. A., Scheller, J., & Rose‐John, S. (2011) · Journal of Clinical Investigation · doi:10.1172/jci57158 · Cited by 694
Gabay, C., Emery, P., van Vollenhoven, R., Dikranian, A., Alten, R., Pavelka, K., Klearman, M., Musselman, D., Agarwal, S., Green, J., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(13)60250-0 · Cited by 672
van de Putte, L. B. A., Atkins, C., Malaise, M., Sany, J., Russell, A. S., van Riel, P. L. C. M., Settas, L., Bijlsma, J. W. J., TODESCO, S., Dougados, M., et al. (2004) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2003.013052 · Cited by 626
Cited by
Targeting Interleukin-6 Signaling in Clinic
Kang, S., Tanaka, T., Narazaki, M., & Kishimoto, T. (2019) · Immunity · doi:10.1016/j.immuni.2019.03.026 · Cited by 904
Metadata
- Authors
- Taylor, P. C., Schiff, M. H., Wang, Q., Jiang, Y., Zhuang, Y., Kurrasch, R., Daga, S., Rao, R., Tak, P. P., & Hsu, B.
- Venue
- Annals of the Rheumatic Diseases
- Publisher
- Elsevier BV
- Published
- 2018-05
- Volume
- 77
- Issue
- 5
- Pages
- 658-666
- ISSN
- 0003-4967
- Cited by
- 28
- References
- 27
- Language
- en
- Funders
- Janssen Research & Development, LLC
- GlaxoSmithKline
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
